Loomis Sayles Announces Changes to Disciplined Alpha Team
19.5.2025 21:19:00 CEST | Business Wire | Press Release
Loomis, Sayles & Company, the global investment manager with nearly $390 billion in assets under management as of 31 March 2025, has announced that Lynne Royer, co-head and portfolio manager of the Disciplined Alpha Team, will retire at the end of 2025 following a remarkable investment career spanning four decades. Additionally, longtime portfolio manager Brad Stevens, CFA, has been promoted to co-head of the team alongside Lynne and Seth Timen, who has co-led the team since 2021.
Known for an intense focus on relative value investing and a proprietary risk-adjusted framework for making security selection decisions, the Disciplined Alpha Team manages over $22 billion in assets as of 31 March 2025.
Lynne will step down from her portfolio management and team co-head roles in October 2025 and will serve as senior advisor to the team through the end of December. Brad and Seth will work closely together on the oversight of Disciplined Alpha portfolios, as well as management of the team, leveraging Seth’s extensive fixed income trading experience and Brad’s fundamental research roots.
Since joining Loomis Sayles in 2010 as a credit analyst, Brad has consistently demonstrated leadership, investment excellence and a deep commitment to Disciplined Alpha’s distinct investment philosophy. Following a promotion to senior credit analyst, in 2018 he was named a credit portfolio manager responsible for idea generation and security selection, a role he will retain for select industries while transferring some sector coverage to others.
“Among Lynne’s many contributions to Loomis Sayles was effectively building a deep bench of investment professionals for the Disciplined Alpha Team together with Seth,” said David Waldman, chief investment officer of Loomis Sayles. “Brad’s promotion is well-earned and represents a natural next step for the team, which is positioned to continue delivering strong results for clients under his and Seth’s leadership.”
Lynne began her investment career in 1985 and joined Loomis Sayles as the co-head and co-founder of the Disciplined Alpha platform in 2010. In addition to shaping the team’s investment philosophy and approach, Lynne contributed significantly to Loomis Sayles’ culture as co-founder of the firm’s first employee resource group, Women@Work.
“Over the last 15 years, Lynne’s leadership has been a driving force behind the growth of the Disciplined Alpha Team’s best-in-class product platform,” said Kevin Charleston, chief executive officer of Loomis Sayles. “We are immensely grateful for Lynne’s dedication to both clients and colleagues and wish her the best as she pursues her passions in retirement.”
ABOUT BRADLEY STEVENS, CFA
Brad Stevens is a portfolio manager and co-head of the Disciplined Alpha Team at Loomis, Sayles & Company. Prior to being named co-head of the team in 2025, Brad was a credit portfolio manager on the team, responsible for idea generation and security selection within his sectors. Brad began his investment industry career in 2000. Prior to joining Loomis Sayles in 2010, he worked at the California Public Employees’ Retirement System as an investment officer in credit. Prior to this, Brad traded equity options at Timber Hill LLC. He earned a BA in economics from Denison University and an MBA from Columbia Business School. Brad is a CFA® charterholder.
ABOUT SETH TIMEN
Seth Timen is a portfolio manager and co-head of the Disciplined Alpha Team at Loomis, Sayles & Company. Seth was named co-head of the team in 2020. He began his investment industry career in 2001 and joined Loomis Sayles in 2010 from Pequot Capital Management, where he was responsible for trading fixed income risk across investment grade, high yield, and structured products. Previously, Seth was an associate at Credit Suisse, where he assisted with corporate bond investment and strategy execution for institutional clients. He earned a BA from the University of Michigan.
ABOUT LOOMIS SAYLES
Since 1926, Loomis, Sayles & Company has helped fulfill the investment needs of institutional and mutual fund clients worldwide. The firm’s performance-driven investors integrate deep proprietary research and risk analysis to make informed, judicious decisions. Teams of portfolio managers, strategists, research analysts and traders collaborate to assess market sectors and identify investment opportunities wherever they may lie, within traditional asset classes or among a range of alternative investments. Loomis Sayles has the resources, foresight and the flexibility to look far and wide for value in broad and narrow markets in its commitment to deliver attractive, risk-adjusted returns for clients. This rich tradition has earned Loomis Sayles the trust and respect of clients worldwide, for whom it manages $390.1 billion* in assets (as of 31 March 2025).
*Includes the assets of both Loomis, Sayles & Co., LP, and Loomis Sayles Trust Company, LLC. ($33.9 billion for the Loomis Sayles Trust Company). Loomis Sayles Trust Company is a wholly owned subsidiary of Loomis, Sayles & Company, L.P.
SAIFiitxkace
View source version on businesswire.com: https://www.businesswire.com/news/home/20250519835097/en/
Contacts
Kate Sheehan
(617) 960-4447
ksheehan@loomissayles.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom